MedTrace Logo

Diagnostic Value of Sonazoid Contrast-enhanced Ultrasound in Renal Tumors

NCT04626115 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2020-11-12

No results posted yet for this study

Summary

The incidence and mortality of renal cell carcinoma are increasing year by year. Contrast-enhanced ultrasound is helpful for early diagnosis and treatment to renal tumor, and is of great importance to distinguish benign from malignant and clinical stages

Conditions

  • Contrast Enhanced Ultrasound

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Ping Liang, doctor · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-03-31
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626115 on ClinicalTrials.gov